One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.
by marketwire, translated by daniel pedersen
US-based investment bank Jefferies has started its coverage of GN Group off with the negative recommendation ”underperform” and a share price target of DKK 115 (USD 15.3), an analysis predicting an increased risk of a planned refinancing states.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.